Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Opthea Limited Sponsored ADR ( (OPT) ) has issued an update.
Opthea Limited announced that its CEO, Frederic Guerard, will present at the 43rd Annual J.P. Morgan Healthcare Conference, providing an update on the company’s Phase 3 trials for sozinibercept, a treatment for wet AMD. This presentation is significant for stakeholders as it may impact Opthea’s market position by showcasing progress in their clinical trials, potentially influencing investor confidence and partnerships.
More about Opthea Limited Sponsored ADR
Opthea Limited is a biopharmaceutical company focused on developing novel therapies to address unmet needs in the treatment of prevalent and progressive retinal diseases, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is undergoing pivotal Phase 3 clinical trials aimed at improving efficacy when combined with standard-of-care anti-VEGF-A therapies.
YTD Price Performance: 7.12%
Average Trading Volume: 30,176
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $498M
For a thorough assessment of OPT stock, go to TipRanks’ Stock Analysis page.
